Vaccines to Prevent Cancer Before It Starts: What Is Proven and What Is Being Studied

The proven route runs through infections

No vaccine in routine use targets cancer cells directly in healthy people. The ones that work take an indirect path. They stop a virus, and stopping the virus lowers the risk of a cancer that virus can cause.

That is a narrower claim than "a vaccine prevents cancer." It is also the claim the evidence supports.

HPV: the strongest case

The HPV vaccine covers types 16 and 18, which cause about 70 percent of cervical cancers and a higher share of some other HPV-caused cancers. It also covers types 31, 33, 45, 52, and 58, which account for another 10 to 20 percent.

CDC recommends it for children and adults ages 9 through 26, routinely at age 11 or 12. It is FDA approved through age 45, but NCI notes it is not routinely recommended for adults 27 through 45, because more people in that group have already been exposed.

Timing drives the benefit. Protection is greatest before first exposure to the virus. The vaccine prevents infection. It does not clear an infection someone already has.

The outcome evidence has caught up. NCI reports that real-world data now show the vaccine greatly reduces cancer rates, not just infections. Protection against the targeted types has lasted more than a decade so far.

Hepatitis B: a more careful claim

Chronic hepatitis B infection can cause liver cancer, and a vaccine exists.

NCI's wording on the benefit is precise, and worth quoting closely. Preventing HBV infection by vaccinating newborns has been shown to lower the risk of liver cancer in children. It is not yet known whether being vaccinated lowers the risk of liver cancer in adults.

That is a real limit, stated by the source itself. It shows what an honest prevention claim looks like when the follow-up time is not there yet.

What is still experimental

A different idea is being tested: vaccines for people at high inherited risk, aimed at precancer rather than at a virus.

Lynch syndrome is the main testing ground. People with it have a high lifetime risk of colorectal and other cancers.

One NCI-sponsored study, listed as NCT05419011, shows what that research looks like today.

• It is a phase 2b trial.
• It tests a set of three vaccines called Tri-Ad5, given with an immune-boosting agent.
• Planned enrollment is 186 people.
• The main measure is how many participants develop adenomas, advanced adenomas, or colon cancer.
• It is listed as active but no longer recruiting.

Note the endpoint. It counts polyps and cancers over time. Prevention trials are slow by design, because you have to wait for events that may never happen.

Nothing in this line of work is available outside a study. Our page on how clinical trials work explains what a phase 2 result can settle.

Reading the next headline

• Ask whether the vaccine targets a virus or a cancer cell.
• Ask whether the outcome measured was infection, precancer, or cancer.
• Ask how long the follow-up ran.
• Ask whether the group studied includes people like you.

Vaccines do not replace screening

Vaccination sits alongside the rest of cancer prevention, not above it. Screening still finds cancers that vaccines do not prevent. Cervical screening remains recommended for vaccinated people, because the vaccine does not cover every high-risk HPV type.

Our page on vaccines that prevent cancer covers eligibility in more detail.

Ask at your next checkup

• Am I or my child due for HPV vaccination?
• Was I vaccinated against hepatitis B, and should I be tested?
• Does my family history suggest genetic counseling?
• What screening do I still need after vaccination?

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.